Fovero Therapeutics is an Australian biotechnology company developing a new immunotherapy for treating immuno-oncology (IO) resistant cancer patients.

We have leveraged cutting-edge research in the field of dysregulated immune function, to develop a novel solution that holds the potential to transform patient care.

At the core of our scientific endeavors, lies the profound understanding that malaria, cancer, and autoimmune diseases share a common etiology—dysregulated immune function. This key insight forms the foundation upon which our research and development efforts are built.

Our proprietary Galectin-9 platform leverages this unique insight in dysregulated immune function to overcome IO resistance in solid tumours.

The lead antibody  improves the efficiency of multiple immune cells to kill cancer cells. In pre-clinical models, our anti-GAL9 treatment completely controlled primary CT26 colon and 4T1.2 triple negative breast cancer.

Our promising new strategy, of modulating GAL9 to enhance immune regulation and kill cancer cells, is differentiated from competing IO therapies targeting individual checkpoint or costimulatory molecules.